Double Bond Pharmaceutical manufactures first GMP batch of SI053

Double Bond Pharmaceuticals contract manufacturer of SI053 reports that they have successfully manufactured the first GMP batch. The batch is to be used among other things for the stability study for SI053.

“There is a lot of work behind this batch and we are very pleased to be able to start the stability study according to plan” says Charlotte Karlsson, Quality Assurance Manager and coordinator of the manufacturing projects.

“Getting a material for future clinical trials is an important milestone in the drug development process” commented Igor Lokot, CEO of Double Bond Pharmaceutical.

More about SI-053

Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. The product has a working name SI-053 in DBP pipeline.

More about our products

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15 of August 2018.

Contact information

Full Company Name:  

Double Bond Pharmaceutical International AB (publ)

Corporate identity:      

556991-6082

Stock short name:      

DBP B

Share ISIN code:        

SE0007185525

For more info, contact
Igor Lokot, CEO

Homepage:

http://www.doublebp.com/

E-mail:

info@doublebp.com

Blog:

http://blog.doublebp.com/en/

Follow us on:

LinkedIn, Facebook and Twitter

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.